Shares of QYUNS-B (02509) have risen more than 8%. At the time of writing, the stock is up 8.12% to HK$16.65, with a turnover of HK$1.4438 million.

On the news front, the Center for Drug Evaluation website recently showed that the company's CLD-423 injection has been approved for clinical trials, intended for the treatment of Crohn's disease. Public information indicates that QX030N/CLD-423 is a bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways, developed for treating inflammatory bowel disease and other immune and inflammatory disorders.

Additionally, the company recently announced its intention to acquire approximately 34.0001% equity in Saifusi, aiming to facilitate the smooth submission and approval of New Drug Applications for its core pipeline products, Lusekimab (QX002N, an anti-IL-17A monoclonal antibody) and Autokimab (QX005N, an anti-IL-4Rα monoclonal antibody).

Analysts have previously noted that the company's long-acting bispecific antibody products have seen a series of overseas licensing agreements materialize, with commercial collaborations expected to maximize the value of its monoclonal antibody pipeline. This is seen as further solidifying the company's competitive moat in the autoimmune disease field.

It is also believed that the company is a leading domestic innovator in autoimmune drugs. Its mature pipeline is gradually entering a value realization phase, enhancing its self-sustaining capabilities. The successive achievement of overseas licensing deals for its innovative pipeline provides further assurance for the company's stable operations, leveraging partnerships with global giants to access international markets.